CO2022001083A2 - Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados - Google Patents

Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados

Info

Publication number
CO2022001083A2
CO2022001083A2 CONC2022/0001083A CO2022001083A CO2022001083A2 CO 2022001083 A2 CO2022001083 A2 CO 2022001083A2 CO 2022001083 A CO2022001083 A CO 2022001083A CO 2022001083 A2 CO2022001083 A2 CO 2022001083A2
Authority
CO
Colombia
Prior art keywords
antibodies
tissue factor
conjugates
related methods
factor drugs
Prior art date
Application number
CONC2022/0001083A
Other languages
English (en)
Inventor
Jan-Willem Theunissen
Allen G Cai
Thi-Sau Migone
Original Assignee
Iconic Therapeutics Inc
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iconic Therapeutics Inc, Zymeworks Inc filed Critical Iconic Therapeutics Inc
Publication of CO2022001083A2 publication Critical patent/CO2022001083A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se proporcionan anticuerpos que se unen específicamente al factor tisular (TF) humano, conjugados de anticuerpos-fármacos (ADC) antiTF y composiciones que comprenden a los anticuerpos o ADC. También se proporcionan en el presente documento métodos para fabricar y usar los anticuerpos o ADC, tales como métodos terapéuticos y de diagnóstico.
CONC2022/0001083A 2019-07-03 2022-02-01 Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados CO2022001083A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962870644P 2019-07-03 2019-07-03
PCT/US2020/040711 WO2021003399A1 (en) 2019-07-03 2020-07-02 Anti-tissue factor antibody-drug conjugates and related methods

Publications (1)

Publication Number Publication Date
CO2022001083A2 true CO2022001083A2 (es) 2022-05-20

Family

ID=74100836

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001083A CO2022001083A2 (es) 2019-07-03 2022-02-01 Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados

Country Status (20)

Country Link
US (1) US20220257789A1 (es)
EP (1) EP3994150A4 (es)
JP (1) JP2022538908A (es)
KR (1) KR20220029724A (es)
CN (1) CN114222752A (es)
AR (1) AR119346A1 (es)
AU (1) AU2020299398A1 (es)
BR (1) BR112021025720A2 (es)
CA (1) CA3141428A1 (es)
CL (1) CL2021003414A1 (es)
CO (1) CO2022001083A2 (es)
CR (1) CR20220047A (es)
DO (1) DOP2021000268A (es)
EA (1) EA202193309A1 (es)
EC (1) ECSP22007981A (es)
IL (1) IL289138A (es)
MX (1) MX2021015974A (es)
PE (1) PE20221004A1 (es)
TW (1) TW202116357A (es)
WO (1) WO2021003399A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023137399A2 (en) * 2022-01-12 2023-07-20 Iconic Therapeutics Llc Inflammatory disease treatment using anti-tissue factor antibodies
WO2023160651A1 (zh) * 2022-02-24 2023-08-31 苏州信诺维医药科技股份有限公司 一种抗体及其药物偶联物和用途
WO2023172951A1 (en) * 2022-03-09 2023-09-14 Exelixis, Inc. Methods of treating solid tumors with anti-tissue factor antibody-drug conjugates
WO2023196869A1 (en) * 2022-04-05 2023-10-12 Atreca, Inc. Epha2 antibodies
CN116143929B (zh) * 2023-02-03 2023-08-01 北京基科晟斯医药科技有限公司 抗重组人凝血因子VIIa-Fc融合蛋白的抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802782C (en) * 2010-06-15 2018-03-13 Genmab A/S Human antibody drug conjugates against tissue factor
HUE057768T2 (hu) * 2014-09-17 2022-06-28 Zymeworks Inc Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei
HRP20211980T1 (hr) * 2015-04-07 2022-04-01 Alector Llc Protutijela protiv sortilina i postupci njihove upotrebe
JP7437301B2 (ja) * 2017-08-25 2024-02-22 ファイヴ プライム セラピューティクス インク Ｂ７－ｈ４抗体及びその使用方法
BR112020008593A2 (pt) * 2017-11-02 2020-10-20 Genmab A/S método de tratamento de câncer cervical em um indivíduo
CA3083345A1 (en) * 2017-11-27 2019-05-31 Purdue Pharma L.P. Humanized antibodies targeting human tissue factor
JP2021509823A (ja) * 2018-01-04 2021-04-08 アイコニック セラピューティクス インコーポレイテッド 抗組織因子抗体、抗体薬物コンジュゲート、及び関連する方法

Also Published As

Publication number Publication date
AR119346A1 (es) 2021-12-09
KR20220029724A (ko) 2022-03-08
CA3141428A1 (en) 2021-01-07
EP3994150A1 (en) 2022-05-11
TW202116357A (zh) 2021-05-01
IL289138A (en) 2022-02-01
JP2022538908A (ja) 2022-09-06
CN114222752A (zh) 2022-03-22
EA202193309A1 (ru) 2022-03-28
BR112021025720A2 (pt) 2022-06-21
PE20221004A1 (es) 2022-06-15
WO2021003399A1 (en) 2021-01-07
AU2020299398A1 (en) 2022-02-24
CR20220047A (es) 2022-06-23
CL2021003414A1 (es) 2022-09-09
US20220257789A1 (en) 2022-08-18
MX2021015974A (es) 2022-04-26
DOP2021000268A (es) 2022-08-15
ECSP22007981A (es) 2022-05-31
EP3994150A4 (en) 2023-08-02

Similar Documents

Publication Publication Date Title
ECSP22007981A (es) Conjugados de anticuerpos y fármacos anti-factor tisular y métodos relacionados
CO2018008667A2 (es) Conjugados de anticuerpo y fármaco basados en eribulina y métodos para su uso
ECSP19044625A (es) Conjugados anticuerpo-droga para ablación de células madre hematopoyéticas
CO6382188A2 (es) Anticuerpos monoclonales que se unen al hgm-csf y composiciones medicas que los comprenden
PH12020551037A1 (en) Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
CR10308A (es) Anticuerpos monoclonales humanizados para el factor de crecimiento del hepatocito
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
ECSP22010121A (es) Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos
BR112022002720A2 (pt) Formulações de conjugados de benzazepinas e usos das mesmas
AR115566A1 (es) Composiciones y procedimientos para el tratamiento del cáncer
CL2018000131A1 (es) Inmunoconjugados de il22
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
BR112023000455A2 (pt) Tratamento de doença inflamatória que usa anticorpos de fator antitecidual
CL2021002838A1 (es) Anticuerpo anti-bcma conjugado, composiciones que comprenden el mismo, y métodos de fabricación y uso del mismo.
GT200700020A (es) Compuestos y derivados de dibencilamina
UY38265A (es) Conjugados anticuerpo droga para ablación de células madre hematopoyéticas
BR112017028012A2 (pt) Terapia combinada com um conjugado anticorpo- fármaco anti-her2 e um inibidor de bcl-2
BR112022022590A2 (pt) Formulações farmacêuticas de acetato de abiraterona e niraparibe
AR120655A1 (es) Anticuerpos ampliamente neutralizantes contra vih
WO2019089594A8 (en) Combination treatment with antibody-drug conjugates and cytarabine
ECSP23045888A (es) Anticuerpos anti-cd48, conjugados de anticuerpo-fármaco, y usos de los mismos